Elelyso (taliglucerase alfa) for injection, 200 units/vial, single-use vial, Rx only, Distributed...
FDA Drug Recall #D-0005-2019 — Class II — September 19, 2018
Recall Summary
| Recall Number | D-0005-2019 |
| Classification | Class II — Moderate risk |
| Date Initiated | September 19, 2018 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Pfizer Inc. |
| Location | New York, NY |
| Product Type | Drugs |
| Quantity | 12,416 vials |
Product Description
Elelyso (taliglucerase alfa) for injection, 200 units/vial, single-use vial, Rx only, Distributed by Pfizer Labs, Division of Pfizer Inc, NY, NY 10017, NDC 0069-0106-01
Reason for Recall
Lack of assurance of sterility -Reports of loose metal ferrule crimps on vials for injection. The entire cap either lifted or dislodged while attempting to flip off the orange color plastic button.
Distribution Pattern
U.S.A. nationwide. The following countries received product from Lot S91616: Albania, South Africa, Israel, Afghanistan, Rwanda, Botswana, Zimbabwe and Iraq as part of the Compassionate Use Program.
Lot / Code Information
Lot S91616
Other Recalls from Pfizer Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0544-2025 | Class II | Bicillin L-A (penicllin G benzathine injectable... | Jul 10, 2025 |
| D-0545-2025 | Class II | Bicillin L-A (penicillin G benzathine injectabl... | Jul 10, 2025 |
| D-0489-2025 | Class II | DOBUTamine Injection, USP, 250 mg/20 mL (12.5 m... | May 28, 2025 |
| D-0565-2024 | Class II | Labetalol Hydrochloride Injection, USP, 20 mg/4... | May 20, 2024 |
| D-0564-2024 | Class II | Buprenorphine Hydrochloride Injection, 0.3 mg b... | May 20, 2024 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.